Pathogen distribution, antimicrobial resistance, and mortality in febrile neutropenia among adults with hematological malignancies: a single-center cohort study
Mediterranean Journal of Hematology and Infectious Diseases · 2026-10-31 · 18 (1) · e2026082
DOI: 10.4084/mjhid.2026.082 ↗Abstract
Background: Febrile neutropenia (FN) remains a major infectious complication in patients with hematological malignancies, and local epidemiological data are essential for guiding management. Objectives: To characterize the pathogen distribution, antimicrobial resistance profile, and antimicrobial exposures in FN and to evaluate factors associated with 28-day infection-related mortality. Methods: This retrospective single-center cohort included adults with hematological malignancies who developed FN at a tertiary university hospital between April 2022 and September 2024. The primary cohort comprised 156 patients with 226 classical FN episodes. Patient-level analyses were used for clinical outcomes and multivariable analyses, whereas episode-level analyses were used for microbiological and antimicrobial exposure data. Results: Among 73 clinically significant isolates, Gram-negative bacteria predominated (76.7%), mainly Escherichia coli (45.2%) and Klebsiella spp. (24.7%). Meropenem resistance was detected in 6.1% of E. coli and 77.8% of Klebsiella spp. isolates; ceftazidime-avibactam resistance was 3.0% and 33.3%, respectively. Concurrent resistance to both ciprofloxacin and levofloxacin was detected in 75.8% of E. coli and 94.4% of Klebsiella spp. isolates. No MRSA was recovered, while glycopeptides were administered in 38.9% of classical FN episodes. Infection-related mortality was 10.3% and 28-day all-cause mortality was 12.8%. No variable was significantly associated with infection-related mortality in the exploratory multivariable analysis. Conclusions: Gram-negative pathogens predominated, with substantial meropenem resistance among Klebsiella spp. Continuous local resistance surveillance and antimicrobial stewardship are essential. Larger multicenter studies are needed to better define factors associated with infection-related mortality.
EUVIMED